BIOLINERX     Print Page  Close Window

SEC filings
424B5
BIOLINERX LTD. filed this Form 424B5 on 07/26/2017
Entire Document
 

 
 Filed pursuant to Rule 424(b)(5)​
Registration No. 333-205700

PROSPECTUS SUPPLEMENT DATED JULY 26, 2017
(To Prospectus Dated October 16, 2015)
 
8,495,575 American Depositary Shares Representing 8,495,575 Ordinary Shares
2,973,451 Series A Warrants to Purchase 2,973,451 American Depositary Shares
2,973,451 Series B Warrants to Purchase 2,973,451 American Depositary Shares
5,946,902 American Depositary Shares Representing 5,946,902 Ordinary Shares Underlying the Warrants
 

We are offering in a direct placement to BVF Partners L.P. (i) 8,495,575 American Depositary Shares (“ADSs”) representing 8,495,575 of our ordinary shares (the “Ordinary Shares”), par value NIS 0.10 per share, (ii) 2,973,451 Series A warrants to purchase an aggregate of 2,973,451 ADSs at an exercise price of $2.00 per ADS (the “Series A Warrants”), (iii) 2,973,451 Series B warrants to purchase an aggregate of 2,973,451 ADSs at an exercise price of $4.00 per ADS (the “Series B Warrants” and with the Series A Warrants, the “Warrants”), and (iv) an aggregate of 5,946,902 ADSs (the “Warrant ADSs”) representing 5,946,902 of our ordinary shares issuable upon exercise of the Warrants (the “Warrant Shares” and, together with the Ordinary Shares and the Warrants, the “Offered Securities”), pursuant to this prospectus supplement for an aggregate total purchase price of $9,600,000.  Each ADS represents one ordinary share.
 
ADSs representing our ordinary shares are quoted on the Nasdaq Capital Market (the “Nasdaq”) under the symbol “BLRX.”  On July 25, 2017, the last reported sale price of the ADSs on the Nasdaq was US$0.925 per ADS.  Our Ordinary Shares currently trade on the Tel Aviv Stock Exchange (the “TASE”) under the symbol “BLRX.”  On July 25, 2017, the last reported sale price of our Ordinary Shares on the TASE was NIS 3.34, or $0.93 per share (based on the exchange rate reported by the Bank of Israel on such date).  There is no established public trading market for the Warrants, and we do not expect one to develop.  We do not intend to apply to list the Warrants on any securities exchange.
 
Investing in the Offered Securities involves a high degree of risk.  See “Risk Factors” beginning on page S-3 of this prospectus supplement and the documents we incorporate by reference in this prospectus supplement and the accompanying prospectus to read about factors you should consider before investing in the Offered Securities.
 
Neither the Securities and Exchange Commission, the Israeli Securities Authority nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete.  Any representation to the contrary is a criminal offense.
 
Delivery of the Ordinary Shares and the Warrants is expected to be made on or about July 31, 2017.
 
Prospectus Supplement dated July 26, 2017